Lyme Disease Vaccine Market is valued at USD 26.7 Million in 2021 and expected to reach USD 135.9 Million by 2028 with a CAGR of 26.2% over the forecast period.
Lyme Disease Vaccine Market Size, Trends, Competitive, Historical & Forecast Analysis, 2022-2028, Increasing prevalence of Lyme disease infections, and growing clinical trials of new vaccines are major factors anticipated to drive the growth of the Global Lyme Disease Market.
The Lyme disease, also known as Lyme borreliosis, is a vector-borne disease caused by the Borrelia bacterium, which is spread by ticks in the genus. Infected blacklegged ticks when bite to humans the disease is transmitted to humans. Lyme-causing bacteria can gradually travel from the tick’s gut to its salivary glands and then transmit the bacteria to the site of the bite. The symptoms of the disease include fatigue, fever, headache and skin rash. If left untreated, it can spread to heart, nervous system and joints and can be lethal. The vaccine for Lyme disease is under pipeline. Mostly endemic areas people has acquire Lyme disease. Lyme disease vaccination is the best way to protect against the mounting threat of tick-borne diseases.
The Covid-19 pandemic has shown A significant impact on global lyme diseases vaccine market. The Covid-19 outbreak caused stressful situation amongst healthcare industry as WHO declared it pandemic. The vaccine development against covid-19 was the most essential thing during initial stage during pandemic. The bacterial vaccines such as DNA vaccines and clinical trials of various DNA vaccines for Covid-19 are carried out which has been positively impacted the global Lyme disease vaccine market.
The global Lyme disease vaccine market is segmented into on the basis of type, application and region & country level. On the basis of type, the global Lyme disease vaccine market is classified into inactivated vaccine and attenuated vaccine. Based upon application, the global Lyme disease vaccine market is divided into hospital, scientific research and others.
The regions covered in global lyme diseases Vaccine market report are North America, Europe, Asia-Pacific, Latin America and Rest of the World. On the basis of country level, the market of global lyme diseases vaccine market is subdivided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, South East Asia, Middle East Asia (UAE, Egypt, Saudi Arabia) GCC, Africa, etc.
Some of the key players for global Lyme disease vaccine market are:
On December 17th, 2021; Yale University researchers developed a completely exceptional vaccine that in guinea pigs presents safety against infection by the bacterium that causes Lyme disease and should also battle other tick-borne diseases. As an alternative of triggering an immune reaction against a precise pathogen, the innovative vaccine prompts a quick response inside the skin to components of tick saliva, preventive the quantity of time that ticks require to feed on and contaminate the host. The vaccine is delivered by the similar mRNA technology that has proved so helpful against Covid-19.
Newly Developed Vaccine Could Prevent Lyme Disease
On March 2nd, 2021; University of Massachusetts School of medicine had developed a new vaccine that could avoid Lyme disease in humans. The vaccination against the tick-borne disease received federal approval previous year and is now a part of an early clinical test. Work on the vaccine is being spearheaded by Dr. Mark Klempner, a associate of the school’s biologics program who has been performing on a Lyme cure for a decade. The vaccine is being tested on 66 patients in Nebraska, Lincoln, and could be accessible to the public in the spring of 2023.
One of the major factors driving the growth of the global Lyme disease vaccine market is increasing prevalence of Lyme disease vaccine. The best way to protect against the increasing risk of tick-borne diseases is through vaccines. Hence, increasing number of cases of Lyme disease is one of the major factors supplementing the demand for Lyme disease vaccine. For instance; according to Centers for Disease Control and Prevention (CDC); every year there have been 400,000 cases of Lyme disease infections. In addition, another factor fostering the growth of the global Lyme disease vaccine market is rising progress and R & D activities to develop Lyme disease vaccines. The rapid growth in prevalence of Lyme disease and the risk for significant long-term health consequences of those infected has raised the demand of vaccines. Hence, multifaceted efforts are needed to creating better preventive treatments and vaccines. For instance; as per the news published on March 8th, 2021, Pfizer Inc. announced the beginning of another Lyme disease vaccine study, VLA15-221. This VLA15 is under clinical development and the only active Lyme disease vaccine candidate which covers six serotypes prevalent. VLA15 has verified strong immunogenicity and safety data in pre-clinical and clinical studies.
Furthermore, growing clinical trials for new vaccines also drives the global Lyme disease vaccine market. The increasing need for the vaccine against lyme disease and ongoing clinical trials is driving the market growth. For instance; on February 24th, 2021, UMass Medical School developed a preventative shot for Lyme disease, entered clinical trial. A pre-exposure prophylax is used a monoclonal antibody that protects against the disease and it was tested on about 60 volunteers, in Phase I trial. Thus, theses clinical trials are expected to drive the market growth for creating safe vaccines in future.
However, complexity of Lyme diseases development are may hamper the growth of the global Lyme disease vaccine market. In spite of that, need of reinvention of vaccines and drugs against lyme disease are expected to provide some opportunities for the growth of the global lyme disease vaccines market.
North America is expected to dominate the global Lyme disease vaccine market due to the increasing prevalence of Lyme disease, research and development in vaccines and highly developed healthcare infrastructure in this region. For instance; as per Centers for Disease Control and Prevention (CDC), there have been at least 40,000 cases of Lyme disease and other tick-borne diseases have also spread in many areas of the U.S., annually. Thus, increasing number of Lyme disease will expected to increase the market of Lyme disease vaccines for the need of vaccines. In addition, growing number of research and development activities related to the lyme are also supplementing the market growth. For example; as per the news published on February 4th, 2022, Pfizer and Valneva entered in partnership for Phase II clinical trial of VLA15. Moreover, highly developed infrastructure in U.S is also expected to foster the market growth for the development of new vaccines in the forecast period.
Europe is expected to be second largest market for the global lyme disease market due to the increasing prevalence of lyme diseases, increased awareness about lyme disease and growing government funding for the vaccine development in this region. For instance; as per the National Institute for Health and Care Excellence, it is appraised that there are 2,000 to 3,000 new cases of Lyme disease in England and Wales each year. In addition to that, high awareness about Lyme disease is also expected to drive the growth of the market in this region. Moreover, rising government funding for the vaccine development is also expected to augment the market growth. For instance; on August 20th, 2021; the professor in the UK Department of Microbiology, Immunology and Molecular Genetics received $3.4 million from the National Institute of Allergy and Infectious Diseases (NIAID) for studying transmission of ticks and infects humans, which could lead to new ways to treat and diagnose the disease.
|Historical data||2018 - 2021|
|Forecast Period||2022 - 2028|
|Market Size in 2021:||USD 26.7 Million|
|Base year considered||2021|
|Forecast Period CAGR %:||
|Market Size Expected in 2028:||USD 135.9 Million|
|Tables, Charts & Figures:||175|
|Lyme Disease Vaccine Companies||Merial, Pfizer, GlaxoSmithKline, Sanofi Pasteur SA, MedImmune, Hualan Biological Engineering, Janssen Pharmaceuticals, Merck, Bharat Biotech, International, Serum Institute of India Pvt & others|
|Segments Covered||By Type, By Application|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|